KLRK1 and lung carcinoma: To further assess whether targeted blockade of CD73 could enhance the in vivo anti-tumor activity of NKG2D.CAR-NK-92 cells, we established a subcutaneous xenograft model in NSG mice with CD73+ human lung carcinoma A549 cells.